01 — At a Glance
The Test That Everyone’s Taking (But Nobody’s Buying Stock Of)
- 52-Week High / Low₹538 / ₹220
- Q3 FY26 Revenue (TTM)₹792 Cr
- Q3 FY26 PAT (TTM)₹136 Cr
- Full-Year FY25 EPS₹5.76
- Annualised EPS (Q3×4)₹7.28
- Book Value₹33.6
- Price to Book10.7x
- Dividend Yield1.94%
- Debt / Equity0.05x
- 6-Month Return-11.9%
Auditor’s Opening Note: Thyrocare closed Q3 FY26 with a blended 20% revenue growth (+18% consolidated, +20% pathology standalone), 75% profit growth, and a 2:1 bonus issue that turned ₹358 into ₹179 on your screen (then rallied back). The company is processing 49.6 million tests annually, operating 39 labs across India, and somehow still trades at a P/E of 40x when diagnostics comps are at 36x median. The math is so disconnected from reality it might need its own blood test.
02 — Introduction
The Company That Tests Indians, Tests Investors’ Patience
Thyrocare is India’s largest diagnostic testing company by volume. Every morning, 49.6 million humans wake up, skip breakfast (as you do before blood tests), and shuffle into a Thyrocare franchise to contribute to the company’s clinical narrative. Three billion investigations processed annually. Capacity to handle 10 billion. One point three lakh+ touchpoints. The company doesn’t run hospitals. It doesn’t sell medicines. It runs blood work.
And yet — P/E of 40.2x, trading at 10.7x book value, dividend yield of 1.94% (pathetic for India), and somehow still celebrated as a “growth story” by analysts who’ve apparently never heard of mean reversion. The stock was ₹538 in September 2025. It’s ₹358 today. That’s a 33% haircut in four months, even as Q3 FY26 delivered 75% profit growth. The narrative breakdown is so complete, they might as well test for cognitive dissonance.
Founded in the early 2000s, Thyrocare became the first fully NABL-accredited national lab chain in India. Its franchise model — partnering with 10,300+ local hospitals, clinics, labs — meant zero capex, distributed risk, and infinite scalability. It also meant massive working capital swings, path-dependency on franchise quality, and exposure to every third-rate clinic in Rural India. Management took the hard way out: made it work anyway.
But now? A promoter selling 10% stake in October 2025 at ₹1,252/share. A 2:1 bonus issued December 2025 that split the stock and blunted every metric on the spreadsheet. New leadership appointments (COO, CCO) mid-transition. Vimta acquisition underperforming. GLP-1 diagnostics opportunity delayed. And a P/E that screams “sell the strength” to anyone who’s seen a bubble before.
Concall Note (Feb 2026): “We are the only company with a dedicated phlebotomy fleet of 2,000 phlebotomists.” — Thyrocare Management. This is genuinely competitive. It’s also something that costs money to maintain. Whether shareholders benefit remains the real diagnostic.
03 — Business Model: WTF Do They Even Do?
You Bleed. They Test. You Pay. Repeat Quarterly.
The business model is beautifully simple: 929 different tests + 288 package profiles under the Aarogyam brand + Sugarscan glucometers + 10 PET-CT imaging centres + a fractional stake in Tanzania operations. That’s the core. But the real magic is the operating model.
Thyrocare doesn’t own most of its collection points. Instead, it franchises: 10,300+ active franchisees (hospitals, clinics, labs, pharmacies, nursing homes) collect samples, prepaid via API. Samples flow to 39 NABL-accredited labs (India) + 1 in Tanzania for central processing, testing, and report release. Revenue model: charges per test, ~₹36–38 per test blended. Margins: normalized EBITDA at 32–34%. Cash conversion: working capital days improved from 44 to -18 days (meaning they’re paid before they spend — which is Costco-level beautiful if you squint).
The segments: Pathology (93% of revenue in Q2, 92% in full-year), Radiology/Imaging (7%, growing slower), and “Others” (glucometers, wellness packages). Pathology is the franchise + partnerships machine. Radiology is the Nueclear Healthcare PET-CT play (10 centers, focused on cancer screening). Quite honestly, it’s a back-office business operating at front-office volumes.
Tests/Quarter49.6MYoY: +22%
Patients/Quarter4.5MYoY: +14%
Active Franchisees10,300Net +200 Q3
Labs (India)39+2 in Q3
Revenue Per Test Drift: ₹38 in Q2 FY26 → ₹36 in Q3. Management said it’s intentional: discounting sugar tests to drive volume. The irony of a diagnostic company discounting health testing — because apparently health is now a commodity play — is not lost on anyone except the CFO.
💬 Question for you: If diagnostics pricing is falling despite 22% volume growth, what happens when the next recession hits and people stop testing altogether?
04 — Financials Overview
Q3 FY26: The Numbers (And How Confusing They Can Be)
Result type: Quarterly Results (Nine Months FY26) | Q3 FY26 EPS: ₹1.82 | Annualised EPS (Q3×4): ₹7.28 | Full-year FY25 EPS: ₹5.76
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue (Standalone) | 183 | 152 | 180 | +20.3% | +1.7% |
| Revenue (Consolidated) | 196 | 166 | 217 | +18.1% | -9.7% |
| Operating Profit | 58 | 42 | 71 | +38.1% | -18.3% |
| OPM % (Consol) | 30% | 25% | 33% | +500 bps | -300 bps |
| PAT (Consolidated) | 28 | 16 | 48 | +75.0% | -41.7% |
| EPS (₹) — Consol | 1.82 | 1.04 | 3.02 | +75.0% | -39.7% |
The Bonus Confusion: All numbers post December 1, 2025 are on a 2:1 bonus-adjusted share count (post-allotment 15.91 Cr shares vs pre-allotment 7.95 Cr). EPS looks cut in half on the surface, but it’s just cosmetic. FY25 EPS of ₹5.76 was pre-bonus; you can’t directly compare to Q3’s ₹1.82 (post-bonus). Annualised Q3 at ₹7.28 is roughly in line with FY25’s ₹5.76, suggesting mid-to-high teens growth YoY when normalized.
Q3 vs Q2 Decline Red Flag? Consolidated PAT fell 42% QoQ (₹48 Cr to ₹28 Cr). Revenue fell 10% QoQ. Looks catastrophic. Management said: festive season softness (Q3 is inherently softer), plus exceptional items (₹6 Cr one-time labor code provisions). Plus Vimta underperformance (acquisition integration). Normalize the exceptional items and Q3 is actually growing nicely YoY. Just not sequentially impressive.
05 — Valuation: Fair Value Range
Is ₹358 Genuinely Overpriced? Let’s Do The Math.
